Initial Discovery

RLBN1001: A highly active drug prototype

A prototype drug (RLBN1001) was tested in more than 370 patients for non-metabolic uses over a 10-year period. Acquist investigators first observed that this drug very rapidly reduced serum uric acid to an extremely low level.

With this clinical proof-of-concept, Acquist pursued this lead by identifying each of the underlying biologic mechanisms that produced this unusually potent activity. Acquist then synthesized a library of novel derivative compounds that enhanced these activities and also reduced risks of potential side-effects.